Weiss Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Weiss Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,910	Closed	-$263K	–	376
2024 Q1	$263K	Sell	1,910 -12,586	-87%	-$1.72M	0.01%	245
2023 Q4	$1.91M	Buy	+14,496	New	+$1.67M	0.09%	109
2022 Q4	–	Sell	-3,500	Closed	-$372K	–	619
2022 Q3	$372K	Buy	+3,500	New	+$355K	0.01%	547
2018 Q4	–	Sell	-7,865	Closed	-$967K	–	477
2018 Q3	$967K	Hold	7,865	–	–	0.07%	100
2018 Q2	$773K	Hold	7,865	–	–	0.08%	101
2018 Q1	$652K	Hold	7,865	–	–	0.05%	107
2017 Q4	$610K	Buy	7,865 +4,358	+124%	+$297K	0.05%	106
2017 Q3	$215K	Buy	+3,507	New	+$185K	0.02%	90

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Weiss Asset Management's NBIX Position: Q2 2024 in Review

Weiss Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 1,910 shares — an estimated $263K sold.

Weiss Asset Management first reported a position in NBIX in Q3 2017 and held it in 8 quarters. The position peaked at $1.91M in Q4 2023. 595 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

Weiss Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
Weiss Asset Management sold 1,910 Neurocrine Biosciences shares in Q2 2024, an estimated $263K.
Weiss Asset Management first reported a position in Neurocrine Biosciences in Q3 2017 and held it in 8 quarters.
Weiss Asset Management's Neurocrine Biosciences position peaked at $1.91M in Q4 2023.
595 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Weiss Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.